INTRODUCTION
All-ScaleFlow™ – a revolutionary approach to the scale-up and production of mRNA-based vaccine and therapeutics
Dillico’s game-changing All-ScaleFlow™ technology offers an entirely new approach to mRNA-LNP manufacturing. All-ScaleFlow™ spells the end of multi-step scale-up and batch production processes, because it enables a single piece of equipment and one set of process parameters to manufacture any volume between 1,000 and 10 million doses. This simplifies and improves the development of mRNA vaccines and therapies, while removing major manufacturing roadblocks.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
NEWS
Dillico to take advantage of Rhône-Alpes and Grenoble’s strong academic and high-technology industrial roots
Dillico is located in Grenoble, in the French Alps. It is not only a beautiful region, but also a place with a strong local environment to support future growth. GRENOBLE Highest density of [...]
Welcome!
We are pleased to welcome you to our new website. Until now, Dillico has remained very discreet, focusing on exchanges with the main players in the mRNA field - we are now entering [...]